Boronic Acid Proteasome Inhibitors With Reversible Selective Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current proteasome inhibitors, such as Carfilzomib, have limitations due to irreversible binding, leading to potential side effects and drug resistance in cancer treatment, necessitating the development of compounds that selectively and reversibly inhibit chymotrypsin-like activity within the proteasome.
Innovation Solution
A boronic acid compound represented by Formula 1, which selectively and reversibly binds to the chymotrypsin-like activity within the proteasome, inhibiting its function while minimizing side effects and allowing for restoration of proteasome function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Carfilzomib is used as a proteasome inhibitor, then chymotrypsin-like activity is inhibited, but irreversible binding causes side effects and drug resistance
Solution Approach 1:
The patent changes the binding parameter from irreversible to reversible by modifying the chemical structure to include a boronic acid group that forms a reversible covalent bond with the serine residue in the chymotrypsin-like active site, thereby maintaining inhibition effectiveness while reducing side effects and drug resistance
Solution Approach 2:
The patent introduces selective binding properties by designing the boronic acid compound to specifically target the chymotrypsin-like active site through local chemical interactions, achieving selective inhibition that spares other proteasome activities and reduces harmful effects on normal cells
2Reliability
If proteasome inhibitors are used to treat cancer, then cancer cell apoptosis is induced, but normal cells are also affected causing side effects
Solution Approach 1:
The patent enhances selectivity by designing the boronic acid compound to specifically bind to the chymotrypsin-like active site structure that is more prominent or accessible in cancer cell proteasomes, thereby inducing apoptosis in cancer cells while minimizing effects on normal cells through reduced off-target binding
3Strength
If irreversible binding is used to ensure inhibitor stability, then binding strength is increased, but utility is limited due to inability to restore function
Solution Approach 1:
The patent transforms the static irreversible binding into a dynamic reversible interaction where the boronic acid compound can bind to and inhibit the proteasome during cancer treatment, then be cleared from the system to allow proteasome function restoration, providing both strong inhibition during treatment and functional recovery afterward
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The boronic acid compound achieves selective inhibition of chymotrypsin-like activity in cancer cells, reducing side effects and maintaining proteasome functionality, offering a promising alternative to existing proteasome inhibitors.
Implementation Method 1
a boronic acid compound selectively and reversibly binds to the chymotrypsin-like activity within the proteasome, inhibiting its function
Data Source
AI summary
The present invention relates to a compound represented by Formula 1, a pharmaceutically acceptable salt thereof, or an isomer thereof, and a pharmaceutical composition for treating or preventing proteasome-mediated diseases, comprising the same as an active ingredient.